Abstract: A radiology workstation (24) includes at least one display component (30, 32); at least one user input device (28); and at least one microprocessor (26, 34) programmed to generate a contextual ranking of clinical codes for a context received via the at least one user input device (28) and to display information pertaining to the contextual ranking on the display component (30, 32) of the radiology workstation (24). The contextual ranking is computed by the microprocessor from (i) statistics of occurrences of the clinical codes in radiology reports contained in a radiology reports database (10) and satisfying the context and (ii) statistics of the clinical codes in problem lists contained in a problem lists database and satisfying the context.

Abstract: The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and flow cytometry detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein.

Abstract: Aspects of the present disclosure are directed to synthetic DNA binding peptides, as well as methods of generating such peptides and methods for use of such peptides in, for example, DNA binding, modifying gene expression, and treatment of various conditions such as cancer, fibrosis, and diabetes. Certain aspects provide synthetic DNA binding dimers comprising two modified bZIP peptides, each comprising a modified basic domain and a modified leucine zipper domain and linked via an interpeptide linker (e.g., a side-by-side interpeptide linker). Also disclosed are universal methods for generating high affinity synthetic DNA binding dimers from any bZIP protein.

Abstract: Aspects of the present disclosure are directed to borealin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such borealin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using borealin-targeting polypeptides.

Abstract: Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.

Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

Abstract: Described herein are novel ?- and ?-propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.

Abstract: The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

Abstract: The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with adduct-forming, complementary reactive side chain moieties.

Abstract: Disclosed, in part, are methods and compositions for evaluating two or more target proteins from the same family through the use of a molecular construct that contains a targeting group and a retrieval tag. The method can, in some aspects, quantify the activity and function of the proteins of interest, visualize active enzymes at the subcellular and intercellular scale, and increase dynamic range via signal amplification.

Abstract: A method for quantum spin amplification includes spin-polarizing an ensemble of quantum spins in an initial spin state to generate a transversely-polarized sensing spin state. The quantum spins identically have an upper energy state and a lower energy state. The sensing spin state accumulates a phase shift that transforms the sensing spin state into a phase-accumulated spin state having first and second transverse polarization components. The phase-accumulated spin state is transformed into an intermediate spin state by rotating the first transverse polarization component into a longitudinal polarization component of the intermediate spin state. The ensemble is then coupled to an auxiliary mode, during which the intermediate spin state evolves such that the second transverse polarization component is amplified into an amplified transverse polarization. This amplified transverse polarization is then measured.

Abstract: Ligand-capped inorganic particles, films composed of the ligand-capped inorganic particles, and methods of patterning the films are provided. Also provided are electronic, photonic, and optoelectronic devices that incorporate the films. The ligands that are bound to the inorganic particles are composed of a cation/anion pair. The anion of the pair is bound to the surface of the particle and at least one of the anion and the cation is photosensitive.

Abstract: Ligand-capped inorganic particles, dispersions of the ligand-capped inorganic particles, and films composed of the ligand-capped inorganic particles are provided. Also provided are methods of patterning the films and electronic, photonic, and optoelectronic devices that incorporate the films. The ligands include bifunctional ligands and two-component ligand systems that include a photosensitive group, cation, or molecule.

Abstract: Methods, compositions and kits are provided to amplify an amount of genomic methylated DNA that can be subsequently analyzed and/or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase/polymerase is used.

Abstract: In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of (i) mesenchymal stem cells (MSCs) or secretome from MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGF?1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); (ii) exosomes produced by MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGF?1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); and/or (iii) exosomes comprising one or more effectors, wherein the one or more effectors comprises, consists essentially of, or consists of (a) miR144, (b) BMP-2, (c) TGF?1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d), and wherein the amount of the effector per exosome is greater than the amount of the effector per exosome when produced by unmodified MSCs.

Abstract: The present disclosure relates to plasmids, systems, and methods for the transformation of Wolbachia. Disclosed herein are plasmids and systems for use in methods of transforming Wolbachia. The inventors have identified extrachromosomal plasmids within Wolbachia. Disclosed herein is a non-naturally occurring plasmid comprising a nucleic acid encoding a transposase. Disclosed herein is a method for transforming a Wolbachia cell, comprising introducing a non-naturally occurring plasmid into the cell, wherein the plasmid comprises a nucleic acid sequence capable of transforming a Wolbachia cell.

Abstract: Qubit devices require fast operation, long coherence, and large scalability to be viable for implementation in quantum computing systems. A qubit platform device having long coherence, scalability, and fast operation includes a substrate, or trap region, configured to structurally support solid neon thereon. A trap electrode is configured to provide a trap voltage to the trap region and which creates a confining electrical field to a confining region adjacent to the trap region. The confining region being a region of space to confine an electron therein, confining the electron against the solid neon. First and second sets of guard electrodes are configured to provide variable electric potentials to first and second guard regions to allow for trapping and manipulation of a single electron in the confining region.

Abstract: Provided herein are compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism. In particular, provided herein are compositions comprising modified peptide YY (PYY) peptides and therapeutic and/or prophylactic methods of use thereof.

Abstract: Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.

Abstract: Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of DNA and RNA cytosine methylation. Certain aspects include methods, compositions and kits useful in bisulfite sequencing of methylated nucleic acids, including methylated nucleic acids from low-input samples such as cell-free DNA and cell-free RNA. Also disclosed are methods and compositions for detection and quantification of 5-hydroxymethylcytosine in DNA.